INMB.US INmune Bio Inc

Healthcare Biotechnology USA Stocks
1.05 USD
Close of Nov 15, 2026
1.01 2.60
Market cap
USD 32.5M
P/E
-
P/B
1.79x
ROE
-84.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is INMB.US undervalued?

Graham number

The Graham number of INmune Bio Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

INmune Bio Inc fundamental analysis

No fundamental analysis for INmune Bio Inc yet.

INmune Bio Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About INmune Bio Inc

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II fo…

Full company profile